妓院一钑片免看黄大片,亚洲av无码成人精品国产,亚洲AV综合色区无码专区桃色,免费A级毛片在线播放不收费

上海醫(yī)藥集團(tuán)股份有限公司（公司簡(jiǎn)稱“上海醫(yī)藥”，上交所股票代號(hào)：601607，港交所股票代號(hào)：02607）是一家總部位于上海的全國(guó)性醫(yī)藥產(chǎn)業(yè)集團(tuán)。公司主營(yíng)業(yè)務(wù)覆蓋醫(yī)藥研發(fā)與制造、分銷與零售全產(chǎn)業(yè)鏈，綜合排名位居全國(guó)醫(yī)藥行業(yè)第二，是中國(guó)唯一一家在醫(yī)藥產(chǎn)品和分銷市場(chǎng)方面均居領(lǐng)先地位的醫(yī)藥上市公司，2012年?duì)I業(yè)收入680億元，位列中國(guó)企業(yè)500強(qiáng)，入選上證180指數(shù)、滬深300指數(shù)樣本股，H股入選恒生指數(shù)成分股、摩根斯坦利中國(guó)指數(shù)（MSCI）。

上海醫(yī)藥研發(fā)以創(chuàng)新為長(zhǎng)期堅(jiān)持的方向，致力于為重大疾病和慢性病提供安全有效的治療藥物，2012年研發(fā)投入占公司制藥業(yè)務(wù)銷售收入4.72%。公司建立了以中央研究院為技術(shù)核心的集團(tuán)總院分院研發(fā)體系，擁有1個(gè)國(guó)家級(jí)企業(yè)技術(shù)中心以及10個(gè)省市級(jí)企業(yè)技術(shù)中心，入選十余項(xiàng)“重大新藥創(chuàng)制”國(guó)家科技重大專項(xiàng)。公司采用開放式研究模式，與中國(guó)科學(xué)院上海藥物所建立了創(chuàng)新藥物研發(fā)戰(zhàn)略聯(lián)盟，與中國(guó)藥科大學(xué)、沈陽(yáng)藥科大學(xué)等建立聯(lián)合實(shí)驗(yàn)室，與日本三菱田邊制藥株式會(huì)社、上海復(fù)旦張江生物醫(yī)藥等合作開展創(chuàng)新藥物研發(fā)；同時(shí)，還通過(guò)項(xiàng)目引進(jìn)、合作開發(fā)等方法開始進(jìn)入治療性抗體領(lǐng)域。

上海醫(yī)藥制造覆蓋化學(xué)和生物藥品、現(xiàn)代中藥和保健品、醫(yī)療器械等領(lǐng)域，產(chǎn)品聚焦心腦血管類、全身性抗感染類、消化系統(tǒng)和免疫代謝類、神經(jīng)精神類、抗腫瘤類五大治療領(lǐng)域，生產(chǎn)片劑、膠囊、粉針（含凍干）、小容量注射液、滴眼劑、氣霧劑、凝膠劑等20種以上劑型，過(guò)億產(chǎn)品20個(gè)。公司旗下的信誼、雷氏、龍虎、青春寶、胡慶余堂、蒼松、國(guó)風(fēng)、神象等多個(gè)品牌為中國(guó)馳名商標(biāo)。公司藥品生產(chǎn)嚴(yán)格執(zhí)行中國(guó)新版GMP要求，有多個(gè)原料藥或制劑通過(guò)了WHO、FDA、歐盟以及其他發(fā)達(dá)國(guó)家的質(zhì)量認(rèn)證。

上海醫(yī)藥的分銷網(wǎng)絡(luò)以中國(guó)經(jīng)濟(jì)最發(fā)達(dá)的華東、華北、華南三大重點(diǎn)區(qū)域?yàn)橹行妮椛淙珖?guó)各地，業(yè)務(wù)規(guī)模排名全國(guó)第二。公司分銷業(yè)務(wù)以醫(yī)院純銷為主，并與全球40多家跨國(guó)藥企開展合作。公司的疫苗、高端耗材、DTP（高值藥品直送）及SPD（醫(yī)藥物流管理技術(shù)）等新業(yè)務(wù)發(fā)展在國(guó)內(nèi)處于領(lǐng)先地位。公司分銷服務(wù)正逐步走向以供應(yīng)鏈延伸服務(wù)和臨床支持服務(wù)為核心的醫(yī)院現(xiàn)代服務(wù)解決方案，為醫(yī)院客戶提供終端解決方案、專項(xiàng)物流和信息化服務(wù)。

上海醫(yī)藥零售擁有華氏、雷允上、余天成、人壽天、雷蒙、科園信海大藥房等諸多知名品牌，覆蓋全國(guó)12個(gè)省、直轄市及自治區(qū)，門店總數(shù)1792家。2012年公司藥品零售銷售規(guī)模居全國(guó)藥品零售行業(yè)前五位，上海華氏大藥房為華東地區(qū)擁有藥房最多的企業(yè)。上海醫(yī)藥的零售業(yè)務(wù)包括連鎖藥店、合辦藥房、DTP 藥房等多種業(yè)態(tài)，并積極發(fā)展電子商務(wù)實(shí)現(xiàn)網(wǎng)上銷售。

上海醫(yī)藥倡導(dǎo)“創(chuàng)新、誠(chéng)信、合作、包容、責(zé)任”的企業(yè)核心價(jià)值觀，致力于持之以恒，提升民眾的健康生活品質(zhì)，努力打造受人尊敬、擁有行業(yè)美譽(yù)度的領(lǐng)先品牌藥制造商和健康領(lǐng)域服務(wù)商。

Shanghai Pharmaceuticals Holding Co., Ltd.(hereinafter as Shanghai Pharma, SSE stock code 601607 and HKEx stock code 02607) is a national pharmaceutical group headquartered in Shanghai, China. The Company’s principal business covers the whole industrial value chain ranging from pharmaceutical R&D, manufacturing, distribution and retailing. The Company is ranked No. 2 in the Chinese pharmaceutical industry in terms of the composite capabilities and is the only listed pharmaceutical company holding aleading position in both pharmaceutical manufacturing and distribution in China. In 2012, the Company had reportedly the business revenues of RMB 68 billion, ranking among the top 500 Chinese enterprises. It is selected into the sample stocks of both the SSE 180 Index and CSI 300 Index, with its H shares selected into the Hang Seng Index Compositional Stocks and MSCI.

Adhering to innovation, Shanghai Pharma’s Research and development is dedicated to providing safe and effective drugs against the grave and chronic diseases. In 2012, the total investment in the R&D accounted for 4.72% of the Company’s manufacturing sales revenue. The Company has built up the R&D systems comprising both the Group’s general institute and the sub-institutes, with the Central Research Institute acting as the technical core. Undertaking over 10 State-level scientific and technological R&D projects of “The development of Major New Drugs”, the Company owns 1 State-level corporate technology center and 10 provincial/city-level corporate technology centers. The Company adopts an open mode of R&D, under which the Company has built up the strategic alliance of innovative drug R&D in collaboration with Shanghai Institute of Materia Medica, built up the joint labs in collaboration with China Pharmaceutical University and Shenyang Pharmaceutical University etc. and has been working together with the Mitsubishi Tanabe Pharma Corporation and Shanghai Fudan Zhangjiang Biopharm etc. in the R&D of innovative drugs. Meanwhile, by means of introducing projects and joint-venture development programs etc., the Company has entered into the area of therapeutic antibodies.

Shanghai Pharma’s manufacturing business provides products ranging from chemical and bio-pharms, modern Chinese medicine, healthcare products and medical devices etc., focusing on five major therapeutic areas as cardiovascular, systemic anti-infections, digestive system and immune-metabolism, neuropsychiatric as well as antineoplastic. The products are made in over 20 dosage forms, including the tablets, capsules, powder (incl. lyophilized form), mini-volume injections, eye-drops, inhalants and coagulants etc. Over 20 products have sales revenue over RMB 100 million. The Company runs a number of brands, such as SINE, Leishi, Dragon & Tiger, Qingchunbao, Huqingyutang, Cangsong, Guofeng and Shengxiang, all of which are the renowned Chinese trademarks. The Company maintains its pharmaceutical production in strict conformity with the latest version of the Chinese GMP, having a number of APIs and preparations passed the quality authentication imposed by WHO, FDA, EU and other developed countries.

Shanghai Pharma’s distribution networks focus on the Eastern China, Northern China and Southern part of China, which are the most developed areas in China, and radiates out to other areas in the country. The Company is ranked No. 2 in China in terms of business scale. The Company has its distribution business dominated by direct sales to hospitals and works strategically with over 40 multinational pharmaceutical companies around the world. The Company boasts to hold a leading position in new business development in China in respect of vaccines, high-end consumables, DTP and SPD. The Company’s distribution services have been gradually upgraded to rendering the modern hospital service solutions focusing on both the extended supply chain services and clinical supportive services, providing the hospital customers with ultimate solutions, specified logistics and information technology services.

Shanghai Pharma runs a number of the renowned brands, including Huashi, Leiyunshang, Yutiancheng, Renshoutian, Leimeng and Keyuanxinhai Pharmacy etc., with a sales network comprising of a total 1,792 drugstores covering 12 provinces, autonomous regions and municipalities. In 2012, the Company was ranked among the top 5 players in the nationwide drug-retailing industry in terms of sales revenues and the Huashi chain Pharmacy runs the largest number of drugstores in East China area. The retailing business of Shanghai Pharma includes diversified business models, comprising the chain drugstores, joint-venture drugstores and DTP drugstores etc. Meanwhile, the Company also takes the initiatives to develop the e-business for sales online.

Adhering to the corporate’s core conceptions that are described as “innovation, integrity, cooperation, inclusiveness and responsibility”, Shanghai Pharma is always dedicated to the enhancement of people’s enjoyment of a healthier living condition, while endeavoring to be recognized as an esteemed manufacturer of the leading-brand pharmaceutical products and service provider in the healthcare industry with a sound reputation.